7 January 2010
[Federal Register: January 7, 2011 (Volume 76, Number 5)]
[Notices]
[Page 1173-1174]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr07ja11-67]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-D-0643]
Draft Guidance for Industry on Electronic Source Documentation in
Clinical Investigations; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance for industry entitled ``Electronic
Source Documentation in Clinical Investigations.'' This document
provides guidance to sponsors, contract research organizations (CROs),
data management centers, and clinical investigators on capturing,
using, and archiving electronic data in FDA-regulated clinical
investigations. It also describes FDA's recommended procedures for
ensuring the reliability, quality, integrity, and traceability of
electronic source data and source records maintained at the site for
FDA inspection.
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that FDA considers your comments on the draft
guidance before it begins work on the final version of the guidance,
submit electronic or written comments on the draft guidance by April 7,
2011.
ADDRESSES: Submit written requests for single copies of the draft
guidance to the Office of Critical Path Programs, Office of the
Commissioner, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 32, rm. 4173, Silver Spring, MD 20993-0002. Send one self-
addressed adhesive label to assist the office in processing your
requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.
Submit electronic comments on the draft guidance to http://
www.regulations.gov. Submit written comments on the draft guidance to
the Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Leonard Sacks, Office of Critical Path
Programs, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg., 32, rm. 4174, Silver Spring, MD 20993-0002, 301-796-8502.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a draft guidance for industry
entitled ``Electronic Source Documentation in Clinical
Investigations.'' This guidance is intended to be used together with
the guidances for industry \1\ entitled:
---------------------------------------------------------------------------
\1\ FDA guidances are available on FDA's Web page at http://
www.fda.gov/RegulatoryInformation/Guidances/default.htm. FDA
guidances are issued and updated regularly. We recommend you check
the Web site to ensure that you have the most up-to-date version of
a guidance.
---------------------------------------------------------------------------
Computerized Systems Used in Clinical Investigations,
Part 11, Electronic Records; Electronic Signatures--Scope
and Application, and
General Principles of Software Validation; Final Guidance
for Industry and FDA Staff.
With the increasing use of computerized systems in clinical
investigations, it is common to find source data documented in an
electronic format, e.g., clinical data initially documented in
electronic health records maintained by hospitals and institutions,
electronic case report forms, laboratory reports that are
electronically generated, electronic medical images from devices, and
electronic diaries provided by study subjects. When paper source
documents are available for review, tracing of data in paper-based
studies can be performed easily. However, when source data is
electronic, the data is traced through complex data capture,
transmission, and archival processes. This guidance recommends
practices that will help ensure that electronic source data and source
records are accurate, legible, original, attributable (e.g., user name
and password), and contemporaneously entered; and meet the regulatory
requirements for recordkeeping and retention.
The following specific topics related to electronic source data are
discussed:
The identification of the data element as the basic unit
of information in the electronic case report form;
The description of a source of each data element;
Information about the electronic creation, modification,
transmission, and storage of source data and documents;
Investigator responsibilities with respect to reviewing
and archiving electronic data;
Transmission of the data to the sponsor and/or other
designated parties; and
Preservation of data integrity.
The draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the Agency's current thinking on capturing,
using, and archiving electronic data in FDA-regulated clinical
investigations. It does not create or confer any rights for or on any
person and does not operate to bind FDA or the public. An alternative
approach may be used if such approach satisfies the requirements of the
applicable statutes and regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) electronic or written comments regarding this document.
It is only necessary to send one set of comments. It is no longer
necessary to send two copies of mailed comments. Identify comments with
the docket number found in brackets in the heading of this document.
Received comments may be seen in the Division of Dockets Management
between 9 a.m. and 4 p.m., Monday through Friday.
III. Paperwork Reduction Act of 1995
This draft guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in Sec. Sec. 312.62(b) and 312.64(b) have
been approved under OMB control number 0910-0014; and the collection of
information in Sec. Sec. 812.140 and 812.150 has been approved under
OMB control number 0910-0078.
[[Page 1174]]
IV. Electronic Access
Persons with access to the Internet may obtain the document at
http://www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/default.htm, http://
www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
default.htm, http://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/GuidanceDocuments/default.htm, and http://
www.regulations.gov.
Dated: January 1, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-73 Filed 1-6-11; 8:45 am]
BILLING CODE 4160-01-P
|